Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impact...
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials
About this item
Full title
Author / Creator
Publisher
Wolters Kluwer Health, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Wolters Kluwer Health, Inc
Subjects
More information
Scope and Contents
Contents
Limitations: The short study duration may not reflect long-term outcomes. Conclusion: Clinically relevant worsening of psoriasis symptoms was associated with substantial worsening of HRQOL. Adalimumab treatment was associated with a substantially reduced risk of clinically relevant worsening.
Alternative Titles
Full title
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A241947525
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A241947525
Other Identifiers
ISSN
1173-2563
